Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923155 | 0.94 | HCRTR1 (0.41) | SCDHCRTR1HCRTR2TP53HTT | |
| SCHEMBL1782074 | 0.89 | SCD (0.47) | SCDGBA1 | |
| SCHEMBL1781823 | 0.88 | HCRTR1 (0.45) | SCDHCRTR1HCRTR2TP53HTT | |
| SCHEMBL1780680 | 0.86 | HCRTR1 (0.47) | SCDHCRTR1HCRTR2TP53HTT | |
| SCHEMBL1781570 | 0.81 | SCD (0.51) | SCDGBA1HSD11B1 | |
| SCHEMBL1781966 | 0.79 | SCD (0.54) | SCDGBA1 | |
| SCHEMBL1780586 | 0.78 | HCRTR1 (0.47) | SCDHCRTR1HCRTR2TP53HTT | |
| SCHEMBL1780313 | 0.78 | HTT (0.51) | SCDHCRTR1HCRTR2HTTKMT2A | |
| SCHEMBL1781932 | 0.77 | DRD4 (0.43) | HTR2AHSD11B1RBP4GRM2 | |
| SCHEMBL1783515 | 0.77 | TP53 (0.46) | SCDTP53HTTKMT2AGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | claimed |
| US-8618287-B2 | Derivatives of triazines and uracils, their preparation and their application in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2013-12-31 | — | — | US | claimed |
| JP-2011528007-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2328886-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | Pierre Fabre Médicament (FR) | 2011-06-08 | — | — | EP | claimed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | claimed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | claimed |
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-8618287-B2 | Derivatives of triazines and uracils, their preparation and their application in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2013-12-31 | — | — | US | disclosed |
| EP-2328886-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | Pierre Fabre Médicament (FR) | 2011-06-08 | — | — | EP | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2011-05-19 | — | — | US | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118266-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | UNG, TYMS, UMPS | SCD 3795/4885HCRTR1 1186/4885HCRTR2 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.